Mymetics Corp (MYMX)

[Work Harder]

We would like to thank David Franco as well as Lucile Warter, Danielle Morelle, and Ulrike Krause at GSK for supplying the RTS,S and AS01 used in this study as well as for their help in the study design. The authors are also to Fergal Hill and Alexandre Levert at

OSIVAX

for their support in respect to the IMX313 nanoparticle platform.

Osivax raises €8M for universal flu vaccine clinical trials

https://www.fiercebiotech.com/biotech/osivax-raises-eu8m-for-universal-flu-vaccine-clinical-trials

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705524/

http://www.imaxio.com/about-us.html